Jubilant Pharmova subsidiary issues preference shares for API business acquisition
Jubilant Pharmova Limited announced today, October 1, 2025, that its wholly-owned subsidiary, Jubilant Biosys Limited (JBL), approved the allotment of 5,15,59,030 Optionally Convertible Redeemable Non-Cumulative Preference Shares (OCRPS). Each share has a face value of ₹10 and was issued at ₹100 per share (including a premium of ₹90), totaling ₹5,15,59,03,000.
This allotment serves as part of the consideration for acquiring the Active Pharmaceutical Ingredients (API) business from JBL on a slump sale basis. The remaining ₹80,00,00,000 of the total consideration for the acquisition was paid in cash, as per the Business Transfer Agreement executed between JBL and the company on June 12, 2025.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when JUBILANT PHARMOVA publishes news
Free account required • Unsubscribe anytime